JP2018522916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522916A5 JP2018522916A5 JP2018506863A JP2018506863A JP2018522916A5 JP 2018522916 A5 JP2018522916 A5 JP 2018522916A5 JP 2018506863 A JP2018506863 A JP 2018506863A JP 2018506863 A JP2018506863 A JP 2018506863A JP 2018522916 A5 JP2018522916 A5 JP 2018522916A5
- Authority
- JP
- Japan
- Prior art keywords
- benzamide
- tert
- butyl
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 46
- 150000001875 compounds Chemical class 0.000 claims 45
- -1 1,1-dioxo-tetrahydro-thiophen-3-yl ring Chemical group 0.000 claims 31
- 239000002253 acid Substances 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 21
- 230000003287 optical effect Effects 0.000 claims 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 18
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 8
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 208000029560 autism spectrum disease Diseases 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 claims 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- QXALUNHYJJONQH-UHFFFAOYSA-N 1,1,1-trifluoro-2-methylpropane Chemical compound CC(C)C(F)(F)F QXALUNHYJJONQH-UHFFFAOYSA-N 0.000 claims 1
- BLZYUPBCMMAQJY-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(2-cyanopropan-2-yl)-5-(4-propan-2-ylpyrimidin-5-yl)benzamide Chemical compound ClC1=CC=C(C=C1)C=1C=C(C(=O)NC(C)(C)C#N)C=C(C=1)C=1C(=NC=NC=1)C(C)C BLZYUPBCMMAQJY-UHFFFAOYSA-N 0.000 claims 1
- IEXCOYKCHHZDAV-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(3-methyl-1,1-dioxothiolan-3-yl)-5-(2-methylpyridin-3-yl)benzamide Chemical compound CC1=NC=CC=C1C1=CC(=CC(=C1)C1=CC=C(Cl)C=C1)C(=O)NC1(C)CCS(=O)(=O)C1 IEXCOYKCHHZDAV-UHFFFAOYSA-N 0.000 claims 1
- WHDQXHVIHYNLIE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(3-methyl-1,1-dioxothiolan-3-yl)-5-(4-propan-2-ylpyrimidin-5-yl)benzamide Chemical compound CC(C)C1=C(C=NC=N1)C1=CC(=CC(=C1)C1=CC=C(Cl)C=C1)C(=O)NC1(C)CCS(=O)(=O)C1 WHDQXHVIHYNLIE-UHFFFAOYSA-N 0.000 claims 1
- FWLXCYJHANUEDT-UHFFFAOYSA-N 3-(4-fluorophenyl)-N-(1-hydroxy-2-methylpropan-2-yl)-5-(4-propan-2-ylpyrimidin-5-yl)benzamide Chemical compound FC1=CC=C(C=C1)C=1C=C(C(=O)NC(CO)(C)C)C=C(C=1)C=1C(=NC=NC=1)C(C)C FWLXCYJHANUEDT-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- LTCIIZCLHRORFY-UHFFFAOYSA-N N-(1-hydroxy-2-methylpropan-2-yl)-3-(4-propan-2-ylpyrimidin-5-yl)-5-[4-(trifluoromethyl)phenyl]benzamide Chemical compound OCC(C)(C)NC(C1=CC(=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C=1C(=NC=NC=1)C(C)C)=O LTCIIZCLHRORFY-UHFFFAOYSA-N 0.000 claims 1
- RUNYMXBKUILPRX-UHFFFAOYSA-N N-(2-cyanopropan-2-yl)-3-(4-propan-2-ylpyrimidin-5-yl)-5-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C(#N)C(C)(C)NC(C1=CC(=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C=1C(=NC=NC=1)C(C)C)=O RUNYMXBKUILPRX-UHFFFAOYSA-N 0.000 claims 1
- VHDXYQYAVCLBLU-UHFFFAOYSA-N N-(2-cyclopropylpropan-2-yl)-3-(4-fluorophenyl)-5-(4-methylpyridin-3-yl)benzamide Chemical compound C1(CC1)C(C)(C)NC(C1=CC(=CC(=C1)C=1C=NC=CC=1C)C1=CC=C(C=C1)F)=O VHDXYQYAVCLBLU-UHFFFAOYSA-N 0.000 claims 1
- RFUHSYKVKXDJDB-UHFFFAOYSA-N N-(2-cyclopropylpropan-2-yl)-3-(4-fluorophenyl)-5-(4-propan-2-ylpyrimidin-5-yl)benzamide Chemical compound C1(CC1)C(C)(C)NC(C1=CC(=CC(=C1)C=1C(=NC=NC=1)C(C)C)C1=CC=C(C=C1)F)=O RFUHSYKVKXDJDB-UHFFFAOYSA-N 0.000 claims 1
- BFRUKUXKDRHTBZ-UHFFFAOYSA-N N-(2-methylbutan-2-yl)-3-(4-methylphenyl)-5-(2-methylpyridin-3-yl)benzamide Chemical compound CC(C)(CC)NC(C1=CC(=CC(=C1)C=1C(=NC=CC=1)C)C1=CC=C(C=C1)C)=O BFRUKUXKDRHTBZ-UHFFFAOYSA-N 0.000 claims 1
- ZZDLYPDMGQKRLK-UHFFFAOYSA-N N-(2-methylbutan-2-yl)-3-(4-methylphenyl)-5-(2-propan-2-ylpyridin-3-yl)benzamide Chemical compound CC(C)(CC)NC(C1=CC(=CC(=C1)C=1C(=NC=CC=1)C(C)C)C1=CC=C(C=C1)C)=O ZZDLYPDMGQKRLK-UHFFFAOYSA-N 0.000 claims 1
- JFOAPTKFBDVMTF-UHFFFAOYSA-N N-tert-butyl-3-(3,4-difluorophenyl)-5-(4-ethylpyrimidin-5-yl)benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C=1C(=NC=NC=1)CC)C1=CC(=C(C=C1)F)F)=O JFOAPTKFBDVMTF-UHFFFAOYSA-N 0.000 claims 1
- JDFYCUZLKSIMSX-UHFFFAOYSA-N N-tert-butyl-3-(4-ethylpyrimidin-5-yl)-5-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C=1C(=NC=NC=1)CC)=O JDFYCUZLKSIMSX-UHFFFAOYSA-N 0.000 claims 1
- FSURMDRHFGQFGK-UHFFFAOYSA-N N-tert-butyl-3-(4-fluorophenyl)-5-(2-methylpyridin-3-yl)benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C=1C(=NC=CC=1)C)C1=CC=C(C=C1)F)=O FSURMDRHFGQFGK-UHFFFAOYSA-N 0.000 claims 1
- GBRVAVNZWCBDOA-UHFFFAOYSA-N N-tert-butyl-3-(4-tert-butylpyridin-3-yl)-5-(4-chlorophenyl)benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C1=CC=C(C=C1)Cl)C=1C=NC=CC=1C(C)(C)C)=O GBRVAVNZWCBDOA-UHFFFAOYSA-N 0.000 claims 1
- UYZVNCNYVHDJFO-UHFFFAOYSA-N N-tert-butyl-3-(4-tert-butylpyridin-3-yl)-5-(4-fluorophenyl)benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C1=CC=C(C=C1)F)C=1C=NC=CC=1C(C)(C)C)=O UYZVNCNYVHDJFO-UHFFFAOYSA-N 0.000 claims 1
- VSXRDIXXFLMDEP-UHFFFAOYSA-N N-tert-butyl-3-(4-tert-butylpyrimidin-5-yl)-5-(3,4-difluorophenyl)benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C1=CC(=C(C=C1)F)F)C=1C(=NC=NC=1)C(C)(C)C)=O VSXRDIXXFLMDEP-UHFFFAOYSA-N 0.000 claims 1
- OTFRFPFKQVKHPZ-UHFFFAOYSA-N N-tert-butyl-3-(4-tert-butylpyrimidin-5-yl)-5-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C(C)(C)(C)NC(C1=CC(=CC(=C1)C1=CC=C(C=C1)C(F)(F)F)C=1C(=NC=NC=1)C(C)(C)C)=O OTFRFPFKQVKHPZ-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15180759.1 | 2015-08-12 | ||
| EP15180759 | 2015-08-12 | ||
| PCT/EP2016/068919 WO2017025523A1 (en) | 2015-08-12 | 2016-08-09 | Pyridine and pyrimidine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522916A JP2018522916A (ja) | 2018-08-16 |
| JP2018522916A5 true JP2018522916A5 (enExample) | 2019-09-26 |
| JP6754828B2 JP6754828B2 (ja) | 2020-09-16 |
Family
ID=53835950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506863A Expired - Fee Related JP6754828B2 (ja) | 2015-08-12 | 2016-08-09 | ピリジン及びピリミジン誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10005736B1 (enExample) |
| EP (1) | EP3334727B1 (enExample) |
| JP (1) | JP6754828B2 (enExample) |
| CN (1) | CN107922391B (enExample) |
| AR (1) | AR105662A1 (enExample) |
| TW (1) | TW201718499A (enExample) |
| WO (1) | WO2017025523A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107207449B (zh) | 2015-04-23 | 2020-11-10 | 豪夫迈·罗氏有限公司 | 用于治疗精神障碍的四唑衍生物 |
| JP6831376B2 (ja) | 2015-10-06 | 2021-02-17 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | トリアゾール誘導体 |
| EP3368522B1 (en) * | 2015-10-28 | 2021-08-04 | F. Hoffmann-La Roche AG | Pyridine or pyrimidine derivatives |
| CN108473462B (zh) | 2016-02-02 | 2021-06-22 | 豪夫迈·罗氏有限公司 | 作为eaat3抑制剂的吡唑-吡啶衍生物 |
| EP3464246B1 (en) | 2016-05-27 | 2020-07-08 | H. Hoffnabb-La Roche Ag | Pyrazol compounds as eaat3 inhibitors |
| CN109563049B (zh) | 2016-10-14 | 2022-11-29 | 豪夫迈·罗氏有限公司 | 作为eaat3抑制剂的咪唑化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080021024A1 (en) * | 2006-06-29 | 2008-01-24 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors |
| WO2010033168A2 (en) * | 2008-09-18 | 2010-03-25 | Renovis, Inc. | Amide compounds, compositions and uses thereof |
| US8598209B2 (en) * | 2008-10-31 | 2013-12-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
-
2016
- 2016-08-09 WO PCT/EP2016/068919 patent/WO2017025523A1/en not_active Ceased
- 2016-08-09 CN CN201680044820.8A patent/CN107922391B/zh not_active Expired - Fee Related
- 2016-08-09 JP JP2018506863A patent/JP6754828B2/ja not_active Expired - Fee Related
- 2016-08-09 EP EP16748125.8A patent/EP3334727B1/en not_active Not-in-force
- 2016-08-10 AR ARP160102450A patent/AR105662A1/es unknown
- 2016-08-11 TW TW105125661A patent/TW201718499A/zh unknown
-
2018
- 2018-02-08 US US15/891,922 patent/US10005736B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522916A5 (enExample) | ||
| RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| RU2016146365A (ru) | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b | |
| JP2013521286A5 (enExample) | ||
| JP2012521428A5 (enExample) | ||
| RU2012142180A (ru) | Ингибиторы катехол-о-метилтрансферазы и их применение для лечения психотических расстройств | |
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| JP2012518634A5 (enExample) | ||
| JP2017505293A5 (enExample) | ||
| JP2017516796A5 (enExample) | ||
| JP2017517538A5 (enExample) | ||
| IL287159B1 (en) | Small molecules agonists for FXR (farnesoid X receptor) and method for their preparation and use | |
| JP2018516873A5 (enExample) | ||
| RU2016104890A (ru) | Производные 1,7-нафтиридина | |
| RU2017107521A (ru) | Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar | |
| EA201590699A1 (ru) | Производные этинила в качестве модуляторов активности рецептора mglur5 | |
| RU2016132858A (ru) | Производные фторнафтила | |
| JP2019513755A5 (enExample) | ||
| JP2013525490A5 (enExample) | ||
| RU2016146560A (ru) | Производные морфолин-пиридина | |
| JP2015536965A5 (enExample) | ||
| JP2012520899A5 (enExample) | ||
| RU2015155438A (ru) | Ингибиторы вирусной репликации, способ их получения и их терапевтические применения |